The Korea Institute of Energy Research (KIER) will invest 11.4 billion won in developing a solvent-free process that does not emit carbon dioxide in electrode manufacturing for lithium-ion batteries.
The process eliminates the 42 kilograms of carbon dioxide emitted by an electric car battery per kilowatt-hour to dry the solvent during the wet electrode manufacturing process.
KIER would be collaborating with three research institutions, two companies, and two universities over the next five years in developing devices and equipment based on the concept of dry processing.
The resulting lithium-ion battery has a 1.6 times higher energy density than existing batteries.
It’s also impossible to extend the thickness of electrode coatings up to a certain level element during the wet manufacturing process, thereby limiting energy density.


NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
BOJ Policymakers Warn Weak Yen Could Fuel Inflation Risks and Delay Rate Action
Oil Prices Slide Nearly 3% as U.S.-Iran Talks Ease Geopolitical Tensions
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
South Korea Factory Activity Hits 18-Month High as Export Demand Surges
Tabletop particle accelerator could transform medicine and materials science
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 



